Design and characterization of nanocrystal formulations containing ezetimibe

Chemical and Pharmaceutical Bulletin

Volumn 59, Issue 1, 2011, Pages 41-45

  Gulsun, Tugba ^a   Gursoy, Reyhan Neslihan ^a   Oner, Levent ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bioavailability; Dissolution rate; Ezetimibe; Nanocrystal; Nanotechnology; Particle size

Indexed keywords

DODECYL SULFATE SODIUM; EZETIMIBE; NANOCRYSTAL; POLOXAMER;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; PARTICLE SIZE; TABLET FORMULATION; X RAY ANALYSIS;

AZETIDINES; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 78650830392     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.59.41     Document Type: Article

References (24)

1. Chan V. S. W., Regul. Toxicol. Pharmacol., 46, 218-224 (2006).
2. Müller R. H., Akkar A., Encyclop. Nanosci. Nanotechnol., 2, 627-638 (2004).
3. 〈http://www.elan.com/Images/Elan-Technology-07v1-tcm3-17145. pdf〉, 19 May 2009.
4. Merisko-Liversidge E., Liversidge G. G., Cooper E. R., Eur. J. Pharm. Sci., 18, 113-120 (2003).
5. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., J. Controlled Release, 111, 56-64 (2006).
6. Yamada T., Saito N., Imai T., Otagiri M., Drug Chem. Pharm. Bull., 47, 1311-1313 (1999).
7. Liversidge G. G., Conzentino P., Int. J. Pharm., 125, 309-313 (1995).
8. Kondo N., Iwao T., Masuda H., Yamanouchi K., Ishihara Y., Yamada N., Haga T., Ogawa Y., Yokoyama K., Chem. Pharm. Bull., 41, 737-740 (1993).
9. Yin S. X., Franchini M., Chen J., Hieh A., Jen S., Lee T., Hussain M., Smith R., J. Pharm. Sci., 94, 1598-1607 (2005).
10. Möschwitzer J., Müller R. H., Eur. J. Pharm. Biopharm., 62, 282-287 (2006).
11. Hecq J., Deleers M., Fanara D., Vranckx H., Amighi K., Int. J. Pharm., 299, 167-177 (2005).
12. Müller R. H., Peters K., Int. J. Pharm., 160, 229-237 (1998).
13. Corrigan O. I., Crean A. M., Int. J. Pharm., 245, 75-82 (2002).
14. Coppola D., Pharm. Technol., 27, 20 (2003).
15. Trotta M., Gallaratea M., Pattarino F., Morel S., J. Controlled Release, 76, 119-128 (2001).
16. Kosoglou T., Statkevich P., Johnson-Levonas A. O., Paolini J. F., Bergman A. J., Alton K. B., Clin. Pharmacokinet., 44, 467-494 (2005).
17. Adin I., Iustain C., U.S. Patent 0234996 A1 (2006).
18. Davis H. R., Int. Cong. Ser., 1262, 243-246 (2004).
19. Wenzel G. W. J., Balaji K. S. S., Koushik K., Navarre C., Duran S. H., Rahe C. H., Kompella U. B., J. Controlled Release, 85, 51-59 (2002).
20. Lee S. H., Lee J. E., Baek W. Y., Lim W. Y., J. Controlled Release, 96, 1-7 (2004).
21. Sistla R., Tata V. S. S. K., Kashyap Y. V., Chandrasekar D., Diwan P. V., J. Pharm. Biomed. Anal., 39, 517-522 (2005).
22. Teeranachaideekul V., Junyaprasert V. B., Souto E. B., Müller R. H., Int. J. Pharm., 354, 227-334 (2008).
23. Bresciani M., Magarotto L., Dobetti L., WO 03/002097 (2003).
24. 〈http://www.fda.gov/cder/guidance/index.htm〉, 12 June 2009.